| Original language | English |
|---|---|
| Pages (from-to) | e135-e137 |
| Journal | British Journal of Haematology |
| Volume | 195 |
| Issue number | 2 |
| DOIs | |
| State | Published - Oct 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Experts’ views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher disease. / Hamiel, Uri; Kurolap, Alina; Cohen, Ian J.; Ruhrman-Shahar, Noa; Hershkovitz, Tova; Niederau, Claus; Zimran, Ari; Revel-Vilk, Shoshana; Istaiti, Majdolen; Cappellini, Maria Domenica; Baris Feldman, Hagit.
In: British Journal of Haematology, Vol. 195, No. 2, 10.2021, p. e135-e137.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Experts’ views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher disease
AU - Hamiel, Uri
AU - Kurolap, Alina
AU - Cohen, Ian J.
AU - Ruhrman-Shahar, Noa
AU - Hershkovitz, Tova
AU - Niederau, Claus
AU - Zimran, Ari
AU - Revel-Vilk, Shoshana
AU - Istaiti, Majdolen
AU - Cappellini, Maria Domenica
AU - Baris Feldman, Hagit
N1 - Funding Information: Ian J. Cohen has received honoraria for scientific talks, grants and advice from: Sanofi‐Genzyme, Protalix, Pfizer and Takeda‐Shire. Noa Ruhrman‐Shahar has received honoraria for scientific talks, grants and advice from: Sanofi‐Genzyme, Pfizer and Takeda‐Shire. Tova Hershkovitz has received honoraria for scientific talks, grants and advice from: Sanofi‐Genzyme, Pfizer and Takeda‐Shire. Claus Niederau has received honoraria for scientific talks, grants and advice from: Abbvie, Alexion, Biogen, Falk, Sanofi‐Genzyme, Gilead, MSD and Takeda‐Shire. The SZMC Gaucher Unit receives support from Sanofi/Genzyme for participation in the ICGG Registry, from Takeda for the GOS Registry and Pfizer for TALIAS. The Unit also receives research grants from Takeda, Pfizer, Sanofi‐Genzyme and Centogene. Ari Zimran receives honoraria from Takeda, Pfizer, Sanofi and BioEvents and consultancy fees from Takeda, AVOBIO, Insightec, Todos Medical and Prevail therapeutics. Shoshana Revel‐Vilk receives grant/research support, honoraria and advisory fee from Takeda, Pfizer and Sanofi‐Genzyme. Maria Domenica Cappellini is a member of the advisory board for: BMS/Celgene, Sanofi‐Genzyme, Novonordisk, Vertex/CRISPR and Vifor. Hagit Baris Feldman has received honoraria for scientific talks, grants and advice from: Sanofi‐Genzyme, Protalix, Pfizer and Takeda‐Shire. The remaining authors declare that they have no competing interests.
PY - 2021/10
Y1 - 2021/10
UR - http://www.scopus.com/inward/record.url?scp=85109171876&partnerID=8YFLogxK
U2 - 10.1111/bjh.17693
DO - 10.1111/bjh.17693
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 34227097
AN - SCOPUS:85109171876
VL - 195
SP - e135-e137
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -